menu
    • menu

    Company profile for Bold Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bold Therapeutics is a clinical stage biotechnology company developing a first-in-class cancer therapy for the treatment of gastric, pancreatic, colorectal and other cancers in combination with existing anti-cancer therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bold TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    850 W Hastings St, Suite 515, Vancouver, British Columbia V6C 3N9, CA
    Telephone
    Telephone
    +1 (604) 262-9899
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bold-therapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bold-therapeutics-inc/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bold Therapeutics Presents Poster on BOLD-100 at AACR 2025
    Bold Therapeutics Presents Poster on BOLD-100 at AACR 2025

    30 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-presents-late-breaking-poster-on-bold-100s-unique-ability-to-mitigate-oxaliplatin-induced-peripheral-neuropathy-oipn-at-aacr-annual-meeting-2025-302442129.html

    PR NEWSWIRE
    30 Apr 2025
    Share Share
    Bold Therapeutics's BOLD-100 May Prevent Oxaliplatin Nerve Damage
    Bold Therapeutics's BOLD-100 May Prevent Oxaliplatin Nerve Damage

    28 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-announces-presentation-of-late-breaking-data-on-bold-100s-unique-ability-to-mitigate-oxaliplatin-induced-peripheral-neuropathy-oipn-302439701.html

    PR NEWSWIRE
    28 Apr 2025
    Share Share
    Bold's BOLD-100 Shows Safety, Efficacy In Biliary Tract, Gastric Cancers
    Bold's BOLD-100 Shows Safety, Efficacy In Biliary Tract, Gastric Cancers

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-announces-positive-phase-2-safety-and-efficacy-results-for-bold-100-in-advanced-metastatic-biliary-tract-and-gastric-cancers-at-asco-2024-302161951.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024
    BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024

    05 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-100-and-atr-inhibitors-as-a-new-avenue-for-pdac-targeting-at-aacr-2024-302108994.html

    PR NEWSWIRE
    05 Apr 2024
    Share Share
    Bold Therapeutics Announces Positive Phase 2 Efficacy Results for BOLD-100
    Bold Therapeutics Announces Positive Phase 2 Efficacy Results for BOLD-100

    22 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-announces-positive-phase-2-safety-and-efficacy-results-for-bold-100-in-advanced-metastatic-colorectal-cancer-at-asco-gi-2024-302040707.html

    PR NEWSWIRE
    22 Jan 2024
    Share Share
    Bold Therapeutics Presents Positive Phase 2 Results for BOLD-100
    Bold Therapeutics Presents Positive Phase 2 Results for BOLD-100

    06 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-presents-positive-interim-phase-2-results-for-bold-100-in-advanced-gastric-and-biliary-tract-cancer-at-asco-2023-301843600.html

    PR NEWSWIRE
    06 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search